|Ver.||Summary||Created by||Modification||Content Size||Created at||Operation|
|1||+ 6064 word(s)||6064||2021-12-29 10:42:20||||
|2||Meta information modification||6064||2021-12-31 07:09:27||| ||
|3||-32 word(s)||6032||2021-12-31 07:14:25||| ||
|4||Meta information modification||6032||2022-01-05 03:20:17||| ||
|5||Meta information modification||6032||2022-01-05 08:04:54||||
Inflammatory bowel disease (IBD) is a chronic, autoimmune disorder of the gastrointestinal tract with numerous genetic and environmental risk factors. Patients with Crohn’s disease (CD) or ulcerative colitis (UC) often demonstrate marked disruptions of their gut microbiome. The intestinal microbiota is strongly influenced by diet. The association between the increasing incidence of IBD worldwide and increased consumption of a westernized diet suggests host nutrition may influence the progression or treatment of IBD via the microbiome. Several nutritional therapies have been studied for the treatment of CD and UC. While their mechanisms of action are only partially understood, existing studies do suggest that diet-driven changes in microbial composition and function underlie the diverse mechanisms of nutritional therapy. Despite existing therapies for IBD focusing heavily on immune suppression, nutrition is an important treatment option due to its superior safety profile, potentially low cost, and benefits for growth and development. These benefits are increasingly important to patients. In this entry, we will describe the clinical efficacy of the different nutritional therapies that have been described for the treatment of CD and UC.